Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005898 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia
A Phase 1 study of Fanconi's Anemia, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00005898: Completed Phase 1 study of Fanconi's Anemia, sponsored by University of Minnesota.
NCT00005898 is a Phase 1 study of Fanconi's Anemia that has completed, run by University of Minnesota. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005898, a Phase 1 study of Fanconi's Anemia, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
OBJECTIVES: I. Determine the probability of engraftment with total body irradiation, cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically identical donor, T-cell depleted hematopoietic cell transplantation in patients with Fanconi's anemia. II. Determine the incidence of acute and chronic graft-versus-host disease in these patients after undergoing this treatment regimen. III. Determine the one-year survival rate in these patients after undergoing this treatment regimen. IV. Determine the toxicity of this treatment regimen in these patients. V. Determine the incidence of relapse in patients with myelodysplastic syndrome or acute myeloid leukemia after undergoing this treatment regimen.
Conditions Studied
Interventions
- DRUG fludarabine
- DRUG cyclophosphamide
- DRUG filgrastim
- DRUG cyclosporine
- DRUG anti-thymocyte globulin
Study Locations (1)
Minnesota
- University of Minnesota Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2000-02 |
| Phase | Phase 1 |
What the finished NCT00005898 record still lists
NCT00005898 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Fanconi's Anemia appearing as the primary indexed condition, and to 5 interventions - of which fludarabine is the first listed.
NCT00005898 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00005898 about?
NCT00005898 is a clinical study titled "Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia". OBJECTIVES: I. Determine the probability of engraftment with total body irradiation, cyclophosphamide, fludarabine, and anti-thymocyte globulin followed by HLA nongenotypically identical donor, T-cell depleted hematopoietic cell transplantation in patients with Fanconi's anemia. II. Determine the i...
What is the current status of trial NCT00005898?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2000-02.
What conditions does trial NCT00005898 study?
This clinical trial studies the following conditions: Fanconi's Anemia.
What interventions are being tested in trial NCT00005898?
The interventions under investigation include: fludarabine (DRUG), cyclophosphamide (DRUG), filgrastim (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00005898?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005898 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fanconi's Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00005898's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia